Tango Therapeutics (TNGX) Non-Current Assets (2020 - 2026)

Tango Therapeutics' Non-Current Assets history runs 7 years deep, the most recent figure standing at $43.5 million for Q1 2026.

• On a quarterly basis, Non-Current Assets fell 11.97% year-over-year to $43.5 million in Q1 2026; TTM through Mar 2026 was $182.5 million, a 10.59% decrease from a year earlier, with the FY2025 full-year figure at $44.9 million, down 10.4% from the prior year.
• Non-Current Assets retreated to $43.5 million in Q1 2026 per TNGX's latest filing, from $44.9 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $62.5 million in Q3 2022 and bottomed at $10.9 million in Q1 2022.
• The 5-year median for Non-Current Assets is $51.6 million (2024), against an average of $48.3 million.
• Biggest YoY gain for Non-Current Assets was 682.88% in 2022; the steepest drop was 93.48% in 2022.
• Year by year, Non-Current Assets stood at $61.2 million in 2022, then dropped by 8.45% to $56.0 million in 2023, then retreated by 10.49% to $50.1 million in 2024, then dropped by 10.4% to $44.9 million in 2025, then decreased by 3.27% to $43.5 million in 2026.
• Per Business Quant, the three latest TNGX Non-Current Assets figures stand at $43.5 million (Q1 2026), $44.9 million (Q4 2025), and $46.4 million (Q3 2025).